Junling Zhang

Shanghai, 201321, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Molecular characterization of FGFR fusion in a large real-world population and clinical utility of bidirectional fusion.

Molecular characterization of FGFR fusion in a large real-world population and clinical utility of bidirectional fusion.

Journal: Chinese medical journal

Published: August 09, 2024

Induction Therapy of Tislelizumab Combined with Cisplatin and 5-Fluorouracil and Subsequent Conversion Surgery in Patients with Unresectable Advanced Esophageal Squamous Cell Carcinoma: A Phase 2, Single Center Study.

Induction Therapy of Tislelizumab Combined with Cisplatin and 5-Fluorouracil and Subsequent Conversion Surgery in Patients with Unresectable Advanced Esophageal Squamous Cell Carcinoma: A Phase 2, Single Center Study.

Journal: Annals of surgical oncology

Published: June 17, 2024

Tumor immune microenvironment analysis of non-small cell lung cancer development through multiplex immunofluorescence.

Tumor immune microenvironment analysis of non-small cell lung cancer development through multiplex immunofluorescence.

Journal: Translational lung cancer research

Published: April 29, 2024

Individual Irinotecan Therapy Under the Guidance of Pre-Treated UGT1A1*6 Genotyping in Gastric Cancer.

Individual Irinotecan Therapy Under the Guidance of Pre-Treated UGT1A1*6 Genotyping in Gastric Cancer.

Journal: Technology in cancer research & treatment

Published: March 18, 2024

Mutation of MET D1228N as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with MET Y1003H Mutation.

Mutation of MET D1228N as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with MET Y1003H Mutation.

Journal: Lung Cancer (Auckland, N.Z.)

Published: March 06, 2024

KMT2C mutation as a predictor of immunotherapeutic efficacy in colorectal cancer.

KMT2C mutation as a predictor of immunotherapeutic efficacy in colorectal cancer.

Journal: Scientific reports

Published: September 10, 2023

Anti-PD-1 plus anti-angiogenesis combined with chemotherapy in patients with HER2-negative advanced or metastatic gastric cancer: a multi-institutional retrospective study.

Anti-PD-1 plus anti-angiogenesis combined with chemotherapy in patients with HER2-negative advanced or metastatic gastric cancer: a multi-institutional retrospective study.

Journal: Journal of gastrointestinal oncology

Published: December 29, 2022

Transformation of ALK-positive NSCLC to SCLC after alectinib resistance and response to combined atezolizumab: a case report.

Transformation of ALK-positive NSCLC to SCLC after alectinib resistance and response to combined atezolizumab: a case report.

Journal: Translational lung cancer research

Published: December 24, 2022

Rare Combined Small Cell Lung Carcinoma and Lung Squamous Cell Carcinoma Response to PD-1 Inhibitor as Third-Line Therapy: A Case Report.

Rare Combined Small Cell Lung Carcinoma and Lung Squamous Cell Carcinoma Response to PD-1 Inhibitor as Third-Line Therapy: A Case Report.

Journal: Cancer management and research

Published: November 15, 2022

Efficacy of intra-arterial chemotherapy with sequential anti-PD-1 antibody in unresectable gastric cancer: A retrospective real-world study.

Efficacy of intra-arterial chemotherapy with sequential anti-PD-1 antibody in unresectable gastric cancer: A retrospective real-world study.

Journal: Frontiers in oncology

Published: August 10, 2022

A Unique Three-Way Variant Philadelphia Chromosome t(6;9;22)(p21.3;q34;q11.2) in a Newly Diagnosed Patient with Chronic Myeloid Leukemia Responded to Flumatinib.

A Unique Three-Way Variant Philadelphia Chromosome t(6;9;22)(p21.3;q34;q11.2) in a Newly Diagnosed Patient with Chronic Myeloid Leukemia Responded to Flumatinib.

Journal: OncoTargets and therapy

Published: June 04, 2022

The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review.

The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review.

Journal: Frontiers in oncology

Published: May 10, 2022

Showing 1-12 of 32

Last Updated: 09/26/2026